TORONTO, Oct. 28, 2020 /CNW/ - The 200+ page eBook is a time capsule chronicle. It is not a news story or a political piece. It is a one-of-a-kindpositive resource comprised of bite-sized essays, breathtaking photographs and poetry, which illuminates the real and relatable thoughts, fears and revelations of 70+ people from North America, Germany and Australia. It is proof positive of what is possible when humanity comes together for the common good. All of the stories resonate with hope and insight, casting a beacon of light to comfort and inspire all. Participants include; a recovered COVID-19 patient, a medical frontline worker, athletes, entertainment leaders, CEO's, faith leaders, thought leaders, entrepreneurs and many more. This compendium is a story about us all. At first blush Finding the Light appears as a glossy coffee-table book, but reveals itself to be an inspiring toolbox; filled with ideas, solutions and perspectives for anyone who has been struggling with their own state of mental well-being due to the pandemic. Inclusive and hopeful, Finding the Lightis for anyone who cares about community and helping one another.
Author Alli Mang shares, "We brought nearly 100 participants together to help bring out the hopeful ideas on how to move forward from this devastating pandemic. I lost my business completely when COVID-19 hit our shores, and like millions of people around the world, I was struggling to figure out how to cope. That's why I created this book. Life is about legacy. Part of our responsibility as leaders is to pay this knowledge forward. The youth charities we have aligned with have significant meaning to me as they involve grief support for children and youth, entrepreneurship, the performing arts, film and television and mentorship for aspiring athletes."
4-time author Alli Mang has been telling stories for more than 35 years on camera, on stage and on the page. She was Canada's first Ivory Girl when campaigns started celebrating the beauty of Moms. She launched a home and lifestyle line selling more than $40 million LIVE on the worldwide shopping channel platform as well as being the only Canadian entrepreneur featured in the 2020 U.S. National magazine, Where Women Create Work. Alli is a master on camera instructor teaching professionals how to make a lasting impact online, on camera and on the page.
$11.99 per eBook download. 50% of every purchase is directed to 3 youth-focused charities:
Lighthouse offers hope and encouragement to grieving children, teens and their families by providing a safe space to share feelings, thoughts and experiences with others who truly understand.
LemonAID Warriors is an award-winning non-profit founded by youth activists, to inspire and empower the next generation of compassionate leaders.
One World Stage and Screen makes high quality training accessible to aspiring youth who lack the financial resources to access the education and mentorship necessary to cultivate their talent in the performing arts, film & television and sports.
SOURCE Alli Mang
CMA-Deloitte report reinforces the urgent need to reduce the backlog of medical services affecting millions of Ontario patients
TORONTO, Oct. 26, 2020 /CNW/ - With COVID-19 cases rising, the findings in the Deloitte report for the Canadian Medical Association (CMA) on the COVID-19-induced surgical backlog reinforce the serious concerns about patient care that the Ontario Medical Association (OMA) has been raising for several months.
"From March to September this year, there were approximately one-third fewer surgical procedures done in Ontario compared to the same period last year," said Dr. Samantha Hill, OMA President and cardiac surgeon. "Doctors are very concerned about the negative downstream effects that this backlog will have on patient health."
COVID-19 has increased Ontario's surgical backlog, as well as the backlog facing other specialists and family doctors and diagnostic services. At least 12.3 million fewer medical services were provided to patients from March to September than the same period last year — a decrease of 18 per cent. Of these, 7.8 million services would have been provided in community-based clinics and 4.5 million services would have been provided in hospitals.
"Clearing the backlog of surgical and other necessary medical services will take a huge financial commitment; the provinces and territories can't do it alone," said OMA CEO Allan O'Dette. "We firmly support Premier Doug Ford's call for the federal government to increase its health-care funding envelope so that patients don't have to wait a minute longer than necessary for the services they desperately need."
The OMA remains committed to working with all levels of the government to provide patients with the care that was delayed during COVID-19 and to reduce current wait times.
To address this backlog, the OMA has made several recommendations including significantly increasing funding to expand operating room hours and the number of beds, and using independent health facilities to create additional physical spaces where surgeries and procedures can be safely performed. This will also help alleviate pressures on hospitals that are already at capacity, enabling more procedures to occur.
"During the second wave of COVID-19, the OMA and government must work together to find solutions that support front-line care, address the health-care backlog, and help the health-care system recover," said Dr. Hill. "Collectively, we need to lead our system to better health. Doing so will also pave the way to a stronger and faster economic recovery."
About the OMA
The Ontario Medical Association represents Ontario's 43,000-plus physicians, medical students and retired physicians, advocating for and supporting doctors while strengthening the leadership role of doctors in caring for patients. Our vision is to be the trusted voice in transforming Ontario's health-care system.
SOURCE Ontario Medical Association
MAVENCLAD® (cladribine tablets) is available through public drug plans for the majority of eligible Canadians with Relapsing-Remitting Multiple Sclerosis
Eligible patients can access PrMAVENCLAD® through public drug plans in seven provinces and two federal programs
MISSISSAUGA, ON, Oct. 27, 2020 /CNW/ - EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, is pleased to announce that eligible patients have access to PrMAVENCLAD® (cladribine tablets) through seven provincial public drug plans including the Régie de l'assurance maladie du Québec (RAMQ) and the Ontario Drug Benefit Exceptional Access Program. This is an important step to ensure broader, equitable and timely access to MAVENCLAD for eligible patients across Canada.
Eligible patients in Alberta, Manitoba, New Brunswick, Nova Scotia, Ontario, Quebec and Saskatchewan living with relapsing-remitting multiple sclerosis (RRMS) can now access MAVENCLAD through their public drug programs. MAVENCLAD is also currently reimbursed by the Non-Insured Health Benefits (NIHB) Program, Veteran's Affairs Canada (VAC) and most private drug insurance plans across the country.
"Patients living with MS can face significant daily and long-term challenges on their journey. Access to new and innovative medications to ease that burden should not pose an obstacle to MS patients," said Dr. Alexandre Prat, Neurologist and Researcher at CRCHUM, Canada Research Chair in Multiple Sclerosis Professor of Neuroscience and Associate Vice-Dean for Clinical Research, Faculty of Medicine, University of Montreal. "The addition of MAVENCLAD, a short course oral treatment, to provincial benefit plans provides a welcomed option for patients and physicians."
MAVENCLAD is available through the majority of the public drug plans following the positive reimbursement recommendations from the Institut national d'excellence en santé et en services sociaux (INESSS) in February 2020 and the CADTH Canadian Drug Expert Committee (CDEC) in October 2018. Negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) were completed in late 2019.
"On average, 11 Canadians are diagnosed with MS every day. Ensuring Canadians have access to all Health Canada approved treatments for MS is vital to help manage their disease and live well," said Pamela Valentine, President and CEO of the MS Society of Canada.
Canada has one of the highest rates of MS in the world, with an estimated 1 in 385 people living with the disease.i EMD Serono, Canada, is committed to supporting those living with the disease and strives to lead innovation in the field of MS.
"We are delighted that the majority of eligible patients with RRMS can access MAVENCLAD through public drug plans," said Robert Woolstencroft, Head of Patient Access & Government Affairs of EMD Serono, Canada. "We continue to work with other participating jurisdictions so eligible patients with RRMS across Canada have timely and equitable access to MAVENCLAD through their public drug plans."
About MAVENCLAD MAVENCLAD (cladribine tablets) is a short-course oral therapy that selectively and periodically targets lymphocytes thought to be integral to the pathological process of relapsing MS.ii In November 2017, Health Canada approved MAVENCLAD (cladribine tablets) as monotherapy for the treatment of adult patients with RRMS to reduce the frequency of clinical exacerbations and delay the progression of disability. MAVENCLAD is generally recommended in MS patients who have had an inadequate response to, or are unable to tolerate, one or more therapies for multiple sclerosis.
MAVENCLAD has been approved in over 80 countries including the United States, European Union (EU), Australia and Switzerland, for various relapsing MS indications.
The clinical development program of MAVENCLAD in MS comprises more than 12,000 patient years of data with over 2,700 patients included in the clinical trial program, and up to 10 years of observation in some patients. These clinical trials include the Phase III CLARITY, CLARITY extension and ORACLE MS trials, the Phase II ONWARD trial and the PREMIERE Long-term Safety Registry.
About Multiple Sclerosis Multiple Sclerosis (MS) is a degenerative autoimmune disease in which the myelin sheath around the nerves in the brain and spinal cord are inflamed and often damaged.iii It is estimated that approximately 2.3 million people have MS worldwide.ivCanada has one of the highest rates of MS in the world with one in 385 people living with the disease.v While symptoms vary, the most common symptoms of MS include extreme fatigue, lack of coordination, weakness, tingling, impaired sensation, vision problems, bladder problems, cognitive impairment and mood changes.vi The relapsing forms of MS are the most common type at the time of diagnosis.vii
About EMD Serono, Canada EMD Serono, Canada, is the Canadian biopharmaceutical business of Merck KGaA, Darmstadt, Germany. EMD Serono, Canada has integrated cutting-edge science, innovative products and devices, and industry-leading patient support and access programs. EMD Serono, Canada has deep expertise in neurology, fertility and endocrinology, as well as a robust pipeline of potential therapies in neurology, oncology, immunology and immuno-oncology. Today, EMD Serono, Canada has more than 100 employees across Canada with headquarters in Mississauga, Ontario.
About Merck KGaA, Darmstadt, Germany Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2019, Merck KGaA, Darmstadt, Germany, generated sales of € 16.2 billion in 66 countries.
The company holds the global rights to the name and trademark "Merck" internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company's technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.
Bayshore HealthCare Partners with Amazon to Donate 1,000 Fire Tablets to Seniors in Need
TORONTO, Oct. 27, 2020 /CNW/ - Bayshore HealthCare, one of Canada's leading home and community care service providers with more than 350,000 clients across the country, has partnered with Amazon to donate 1,000 Fire Tablets to help support isolated seniors, through their Bayshore Foundation for Empowered Living charitable division.
According to Statistics Canada, the impact of social isolation and loneliness on health and wellbeing is a public health issue, with an estimated 525,000 Canadians aged 65 and older who are feeling socially isolated, based on the Canadian Community Health Survey – Healthy Agingi.
Moreover, seniors with health conditions may have a greater need for social support during the COVID-19 pandemic than their healthier counterparts. This group may be at a greater risk of low social support during the pandemic due to social distancing measures implemented to reduce the spread of COVID-19. Seniors who lived alone, seniors who resided in urban areas, senior men, and immigrant seniors were somewhat less likely to have high levels of social support than their counterpartsii.
"Social isolation and loneliness are big challenges for seniors, which have heightened because of the COVID-19 pandemic," says John Lawrence, Director of Bayshore Foundation. "Our mission is to make a difference in the community by providing compassionate care and empowering seniors. We are proud to partner with Amazon on this initiative to help support seniors and ease their loneliness."
As part of this campaign, Bayshore will be donating Fire Tablets through a number of charitable community organizations that support isolated seniors including the University Health Network and Cyber Seniors, as well as other organizations supporting seniors. The tablets can be used to stay in touch with family and friends, who seniors may not be able to see in person because of COVID.
The University Health Network will use the Fire tablets for patients in Toronto Rehabilitation Institute who are unable to visit with family members, and for patients and caregivers to use through their libraries. Cyber Seniors will provide the tablets to seniors in Ottawa, Mississauga and Niagara Region through their intergenerational social activity and learning program that teaches seniors how to use the internet, as well as provides seniors with support, companionship, and connection.
"We support Bayshore's mission to provide care and empower seniors," said Marc Whitten, vice president Amazon Entertainment Devices and Services. "We hope our donation of Fire HD 8 tablets helps continue that mission and provides aging Canadians new ways to stay entertained and connected to loved ones during these challenging times."
Bayshore HealthCare also has a number of other initiatives supporting isolated seniors during COVID-19:
UHN Open Lab Friendly Neighbour Hotline - This program matches community volunteers with isolated seniors to help with grocery shopping and delivery. The Bayshore Foundation for Empowered Living supported this program through a financial donation.
About Bayshore HealthCare: Bayshore HealthCare is one of the country's leading providers of home and community health care services and is a Canadian-owned company. With over 100 locations across the country, including 65 home care offices, 13 pharmacies and 81 community care clinics, Bayshore has more than 13,500 staff members and provides care to over 350,000 clients annually. Its services are purchased by government care programs, insurance companies, workers' compensation boards, health care organizations, the corporate sector and the public. The Bayshore brand extends across four business divisions: Bayshore Home Health (medical and non-medical home care and staffing services), Bayshore Home Care Solutions (home care services for government care programs), Bayshore Specialty Rx (specialty pharmacy, infusion and pharmaceutical patient support services), and CAREpath (health care navigation program with focus on oncology and chronic disease management). The company's goal is to enhance the quality of life, well-being, dignity and independence of Canadians of all ages. In 2017, Bayshore HealthCare launched the Bayshore Foundation for Empowered Living to assist those living with illness, injury or aging reclaim or maintain their independence. As a national charity, we support local charities that provide the tools, programs and services needed to empower these individuals. Bayshore HealthCare has been a recipient of Canada's Best Managed Companies award since 2006.
Pharmacy Brands Canada to Expand PrescribeIT® Service to Banner Members in Western Canada
EDMONTON, AB, Oct. 26, 2020 /CNW/ - Pharmacy Brands Canada is pleased to announce an exciting new partnership with Canada Health Infoway (Infoway) to launch PrescribeIT®, Canada's only national not-for-profit electronic prescribing service. This innovative e-prescribing platform will soon be offered in our mettra Pharmacy, Value Drug Mart, Apple Drugs, Peoples Pharmacy and Rxellence independent community pharmacies across Western Canada.
PrescribeIT® enables physicians and other prescribers to send prescriptions and renewal requests electronically to a patient's preferred pharmacy, resulting in more efficient patient care, enhanced safety, and greater accuracy when filling prescriptions.
In partnership with Infoway and collaboration with provincial ministries, Pharmacy Brands Canada plans to roll out the PrescribeIT® service to independent pharmacy banner locations across Western Canada over the next 12 months.
"We are excited to partner with Infoway to introduce this e-prescription service to our independently owned community pharmacy banner members, their pharmacy teams, patients, allied health partners and communities," said Pauwlina Cyca, Director of Pharmacy Services, Pharmacy Brands Canada. "The PrescribeIT® platform completes the circle of care, and ensures continuity for each patient, every prescription and every pharmacy."
"Infoway is excited about this new partnership with Pharmacy Brands Canada," said Jamie Bruce, Executive Vice President, Infoway. "PrescribeIT® provides safer and more effective medication management and protects patients' personal health information from being sold or used for commercial activities. It's an important step in helping Canadians experience better health outcomes."
PrescribeIT® is a free service offered by health care prescribers and pharmacies. Patients who are interested in using the service may wish to consult with their physician or prescriber.
About Pharmacy Brands Canada
Pharmacy Brands Canada offers a unique banner program to independent pharmacies across Western Canada. We provide a business model that offers tools, resources and support for pharmacy owners to operate successfully within a highly regulated and competitive environment. Pharmacy Brands Canada supports the following banner brands: mettra Pharmacy, Value Drug Mart, Apple Drugs, Rxellence and Peoples Pharmacy. Visit http://pharmacybrandscanada.com/.
About Canada Health Infoway
Infoway helps to improve the health of Canadians by working with partners to accelerate the development, adoption and effective use of digital health across Canada. Through our investments, we help deliver better quality and access to care and more efficient delivery of health services for patients and clinicians. Infoway is an independent, not-for-profit organization funded by the federal government. Visit www.infoway-inforoute.ca.
About PrescribeIT®
Canada Health Infoway is working with Health Canada, the provinces and territories, and industry stakeholders to develop, operate and maintain the national e-prescribing service known as PrescribeIT®. PrescribeIT® will serve all Canadians, pharmacies and prescribers and provide safer and more effective medication management by enabling prescribers to transmit a prescription electronically between a prescriber's electronic medical record (EMR) and the pharmacy management system (PMS) of a patient's pharmacy of choice. PrescribeIT® will protect Canadians' personal health information from being sold or used for commercial activities. Visit www.PrescribeIT.ca.
Incyte Announces Health Canada Acceptance of the New Drug Submission for Pemigatinib as a Treatment for Patients with Cholangiocarcinoma
MONTREAL, Oct. 26, 2020 /CNW/ - Incyte (Nasdaq: INCY) today announced that Health Canada has accepted its New Drug Submission (NDS) for pemigatinib, a selective fibroblast growth factor receptor (FGFR) inhibitor, as a treatment for adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or other rearrangement.
The NDS is based on data from the FIGHT-202 study evaluating pemigatinib as a treatment for patients with previously treated, locally advanced or metastatic cholangiocarcinoma. Study results demonstrated that in patients harboring FGFR2 fusions or rearrangements (Cohort A), pemigatinib monotherapy resulted in an overall response rate (ORR) of 36 percent (primary endpoint), and median duration of response (DOR) of 9.1 months (secondary endpoint) with a median follow-up of 21 months. Adverse events observed included Retinal Pigment Epithelial Detachment (RPED) and hyperphosphatemia. The most common adverse reactions (incidence ≥ 20%) are hyperphosphatemia, alopecia, diarrhea, nail toxicity, fatigue, dysgeusia, nausea, constipation, stomatitis, dry eye, dry mouth, decreased appetite, vomiting, arthralgia, abdominal pain, hypophosphatemia, back pain, and dry skin.
"The need for new therapies for patients with cholangiocarcinoma remains urgent, as they have limited treatment options beyond first-line chemotherapy and often face a poor prognosis," said Josée Brisebois, Ph.D., Head of Medical Affairs, Incyte Biosciences Canada. "We intend to work closely with Health Canada as we seek to bring this innovative targeted therapy to patients suffering from this difficult disease as soon as possible." This NDS marks the first marketing application that Incyte Biosciences Canada has made to Health Canada since establishing operations in Canada in April 2020.
Cholangiocarcinoma is a rare cancer that forms in the bile duct. It is classified based on its anatomical origin: intrahepatic cholangiocarcinoma (iCCA) occurs in the bile duct inside the liver and extrahepatic cholangiocarcinoma occurs in the bile duct outside the liver. Patients with cholangiocarcinoma are often diagnosed at a late or advanced stage when the prognosis is poor.1,2 The incidence of cholangiocarcinoma varies regionally and ranges between 0.3-3.4 per 100,000 in North America and Europe.1 FGFR2 fusions or rearrangements occur almost exclusively in iCCA, where they are observed in 10-16% of patients.3-5,1 FGFRs play an important role in tumor cell proliferation and survival, migration and angiogenesis (the formation of new blood vessels). Activating fusions, rearrangements, translocations and gene amplifications in FGFRs are closely correlated with the development of various cancers.
About FIGHT-202
The FIGHT-202 is a multi-center, open-label, single-arm, Phase 2 study (NCT02924376) that evaluated the safety and efficacy of pemigatinib – a selective fibroblast growth factor receptor (FGFR) inhibitor – in adult (age ≥18 years) patients with previously treated, locally advanced or metastatic cholangiocarcinoma with documented FGFR2 fusion or rearrangement.
Incyte Announces Health Canada Acceptance of the New Drug Submission for Pemigatinib as a Treatment for Patients with Cholangiocarcinoma
Patients were enrolled into one of three cohorts – Cohort A (FGFR2 fusions or rearrangements), Cohort B (other FGF/FGFR genomic alterations) or Cohort C (no FGF/FGFR genomic alterations). All patients received 13.5 mg pemigatinib orally once daily (QD) on a 21-day cycle (two weeks on/one week off) until radiological disease progression or unacceptable toxicity.
The primary endpoint of FIGHT-202 was overall response rate (ORR) in Cohort A, assessed by independent review per RECIST v1.1. Secondary endpoints include ORR in Cohorts B, A plus B, and C; and duration of response (DOR).
The FIGHT (FIbroblast Growth factor receptor in oncology and Hematology Trials) clinical trial program includes ongoing Phase 2 and 3 studies investigating the safety and efficacy of pemigatinib therapy across several FGFR-driven malignancies. Phase 2 monotherapy studies include FIGHT-202, as well as FIGHT-201 investigating pemigatinib in patients with metastatic or surgically unresectable bladder cancer, including with activating FGFR3 mutations or fusions/rearrangements; FIGHT-203 in patients with myeloproliferative neoplasms with activating FGFR1 fusions/rearrangements; FIGHT-207 in patients with previously treated, locally-advanced/metastatic or surgically unresectable solid tumor malignancies harboring activating FGFR mutations or translocations, irrespective of tumor type. FIGHT-205 is a Phase 2 study investigating pemigatinib plus pembrolizumab combination therapy and pemigatinib monotherapy as first-line treatment for metastatic or unresectable bladder cancer harboring FGFR3 mutations or rearrangements who are not eligible to receive cisplatin. FIGHT-302 is a Phase 3 study investigating pemigatinib as a first-line treatment for patients with cholangiocarcinoma with FGFR2 fusions or rearrangements.
About Pemigatinib
Pemigatinib is a potent, selective, oral inhibitor of FGFR isoforms 1, 2 and 3 which, in preclinical studies, has demonstrated selective pharmacologic activity against cancer cells with FGFR alterations.
The safety and efficacy of pemigatinib is under review and the market authorization in Canada has not yet been obtained.
Pemigatinib is marketed by Incyte in the United States. Incyte has granted Innovent Biologics, Inc. rights to develop and commercialize pemigatinib in hematology and oncology in Mainland China, Hong Kong, Macau and Taiwan. Incyte has retained all other rights to develop and commercialize pemigatinib outside of the United States.
About Incyte
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.
Incyte Announces Health Canada Acceptance of the New Drug Submission for Pemigatinib as a Treatment for Patients with Cholangiocarcinoma
Forward Looking Statements
Except for the historical information set forth herein, the matters set forth in this press release contain predictions, estimates and other forward-looking statements, including without limitation statements regarding: whether or when pemigatinib might be approved in Canada, for the treatment of, and whether or when pemigatinib might provide a treatment option for, patients with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements, and the FIGHT clinical trial program. These forward-looking statements are based on the Company's current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA; the Company's dependence on its relationships with its collaboration partners; the efficacy or safety of the Company's products and the products of the Company's collaboration partners; the acceptance of the Company's products and the products of the Company's collaboration partners in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; greater than expected expenses; expenses relating to litigation or strategic activities; and other risks detailed from time to time in the Company's reports filed with the Securities and Exchange Commission, including its Form 10-Q for the quarter ending June 30, 2020. The Company disclaims any intent or obligation to update these forward-looking statements.
References
1.
Banales JM, et al. Nat Rev Gastroenterol Hepatol. 2016;13:261‒280.
2.
Uhlig J, et al. Ann Surg Oncol. 2019;26:1993–2000.
3.
Graham RP, et al. Hum Pathol. 2014;45:1630‒1638.
4.
Farshidfar F, et al. Cell Rep. 2017;18(11):2780–2794.
5.
Ross JS et al. The Oncologist. 2014;19:235–242.
SOURCE Incyte Biosciences Canada
BioCanna Announces A Breakthrough In Development of Its Patent-Pending 'BioNano Virus Detection System' And Announcing the COVID-19 POC Test Kit
TORONTO, Oct. 26, 2020 /CNW/ - BioCanna Health Care Inc., a leading innovator in pharmaceutical applications of Cannabinoids, Terpenes and other biomaterials, has announced that its wholly owned subsidiary, BioCanna CuraLab, in collaboration with University of Ottawa, has made a breakthrough development in its "BioNano Virus Detection System" by innovative application of cutting -edge nanotechnologies.
The state-of-the-art "BioNano Virus Detection System" can detect virus with superior sensitivity, reliability, convenience, timeliness and at an extremely low cost. The detection is an antigen test that does not require any assistance of healthcare professionals or laboratory facilities. As a result, all virus tests can be conducted easily at home, schools, sport and entertainment venues and remote areas at a substantially reduced cost.
BioCanna continues to enhance the system features and tailor to specific virus detections
COVID 19 POC Saliva Test Paper Strip
BioCanna also announce the tailored application of the BioNano Virus Detection System in detecting SARS-CoV-2, the virus that causes the COVID-19, and achieved breakthrough measurable results.
The BioCanna COVID-19 POC KIT, 'ID-COVID-19', directly identifies the SARS-CoV-2 virus by reading the person's saliva sample. A person can self-collect his own saliva sample in anywhere and at any time, and then read the results from the paper stripe within 15 minutes. The entire test process is very simple. The test is ultra-sensitive and with over 95% accuracy rate and at an estimated cost of only CAD$5.00 per test
About BioCanna Healthcare Inc.
BioCanna healthcare Inc. is a leading innovator in the pharmaceutical applications of Cannabinoids, Terpenes and other biomaterials. BioCanna is developing, through vigorous R&D and clinical trials, promising anti-inflammatory and neurological disorder drugs.
Forward-Looking Statements
Certain statements contained in this press release constitute "forward-looking information". The Forward-Looking Information contained in this press release is made as of the date hereof, and BioCanna is not obligated to update or revise any Forward-Looking Information, whether as a result of new information, future events or otherwise, except as required by law. Because of the risks, uncertainties and assumptions contained herein, readers should not place undue reliance on Forward Looking-Information. The foregoing statements expressly qualify any Forward-Looking Information contained herein.
SOURCE Biocanna Healthcare Inc.
Welcome to the Train It Right Life Podcast with Alicia Bell. Today Alicia sits down to discuss comparison, what the heck is wrong with men and failed productivity with procrastination!
Pro-HD, our 100% grass fed whey isolate protein, formulated to be one of the purest, cleanest and what we feel to be the best tasting protein powders on the market today with absolutely zero fillers, blends or amino spiking and zero sugars, artificial flavors or dyes!
Whey Protein Isolate is a superior form of protein and better absorbed by the body when compared to concentrates and blends. We utilize a cross flow microfiltration process when manufacturing to further enhance our product quality helping to eliminate any unwanted impurities and excess fats, cholesterols, and lactose; ultimately enhancing absorption and digestion of Pro-HD and giving you the absolute best quality of protein your body needs. This is further enhanced by the inclusion of DigeSEB®, a unique proven and effective digestive enzyme blend that supports optimal breakdown, digestion and absorption of nutrients, ensuring our protein and other food sources you consume with Pro-HD are effectively utilized by your body.
Integrity is at the forefront of everything we do and protein is a staple in all of our diets which is why we have taken the extra steps necessary to ensure Pro-HD mixes well, tastes phenomenal and is of the upmost quality we can put the HD stamp of approval on.
Union Demands Immediate Action After Another Nurse Attacked at Southlake Regional Hospital
Second nurse a victim of workplace violence in past six days
RICHMOND HILL, ON, Oct. 23, 2020 /CNW/ - SEIU Healthcare, a union representing over 60,000 frontline healthcare workers including over 7,500 nurses, is demanding immediate action by Southlake Regional Hospital, including a meeting with key stakeholders, after a registered practical nurse (RPN) was attacked Thursday evening by a patient, just six days after another nurse suffered severe workplace injuries.
The most recent violent attack comes after the hospital was fined $80,000 on Friday, October 16 in connection with a January 2019 incident when a 21-year-old male patient violently assaulted a registered nurse (RN) and a security guard in the emergency department.
SEIU Healthcare is demanding that Southlake CEO Arden Krystal initiates an urgent meeting with the union, frontline staff members, Ontario Minister of Health and local MPP Christine Elliott, Associate Minister of Mental Health and Additions, Michael Tibollo, and representatives from the mental health and addictions sector to create an action plan that will ensure safety for everyone at the hospital. On Monday, October 26 at 3:30 p.m., there will be a rally held in front of Southlake Hospital to demand an end to workplace violence and a meeting to fix a system that is failing to protect people.
What: Rally Against Workplace Violence When: October 26, 2020 Time: 3:30 p.m. to 4:30 p.m. Where: In front of Southlake Regional Hospital, 596 Davis Dr, Newmarket, Ontario
Quotes:
"The most recent fines that Southlake received were a slap on the wrist that didn't line up with the seriousness of these incidents. The continued violence happening at Southlake Regional Hospital is sickening, heartbreaking and alarming, and it is clear that whatever actions they have taken since the horrendous incidents last January have not been enough. We are demanding Southlake hold an emergency meeting with us to ensure the protection of our frontline healthcare workers." – SEIU Healthcare President Sharleen Stewart
"Nurses across Ontario are already putting their lives on the line each day as they fight COVID-19. Violence in the workplace is something nurses should not have to worry about. If Southlake's leadership can't solve the ongoing violence taking place in their hospital, and it's evident at this point they can't, then the government should immediately step in to fix an underfunded system that puts all hospital workers at risk." - SEIU Healthcare Nursing Division President Jackie Walker
SEIU Healthcare represents more than 60,000 healthcare and community service workers across Ontario. The union's members work in hospitals, homecare, nursing and retirement homes, and community services throughout the province. www.seiuhealthcare.ca
SOURCE SEIU Healthcare
TRAIN IT RIGHT NEWSLETTER
Sign Up and get a free 7 day Train it Right HIIT Program!
